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Abstract 
Background: Gestational diabetes mellitus (GDM) is a significant risk factor for cardiovascular disease (CVD) in later 
life. Pentraxin 3 (PTX3) is an essential component of innate immunity and independently associated with the risk of 
developing vascular events. The aim of the study was to examine the relationships between GDM, cardiovascular risk, 
and plasma PTX3 in pregnancy and at 5 years after the index pregnancy.
Methods: This population-based prospective cohort included 300 women who had an oral glucose tolerance test 
(OGTT) during pregnancy. Five years later, the OGTT was repeated along with dual-energy x-ray absorptiometry, lipid 
analysis, and pulse wave velocity analysis. Fasting PTX3 levels were measured four times during pregnancy and at 
follow-up.
Results: PTX3 levels were lower early in pregnancy and at 5 years follow-up in women who developed GDM. PTX3 
levels throughout pregnancy were associated with body mass index. Low PTX3 levels in early pregnancy were predic-
tive of an increased apoB/apoA ratio at 5-year follow-up. PTX3 at 5-year follow-up was inversely correlated with multi-
ple metabolic risk factors for CVD, including body composition, arterial stiffness, dyslipidemia and previous GDM.
Conclusions: Our results show that low plasma concentration of PTX3 in early pregnancy is associated with sub-
sequent development of GDM and with an enhanced risk for CVD as estimated by an elevated apoB/apoA ratio at 
5 years postpartum.
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Background
Gestational diabetes mellitus (GDM) refers to carbohy-
drate intolerance first diagnosed during pregnancy. It 
is a condition of the pancreatic β-cells, which produce 
inadequate amounts of insulin to meet the increased 
insulin needs of late pregnancy [1]. The pathogenesis of 
GDM is not fully clarified, but seem to involve activa-
tion of inflammatory pathways in addition and related to 
metabolic and endocrine mechanisms [2]. The maternal 
innate immune system is stimulated during normal preg-
nancy, whereas the adaptive immune system is relatively 
suppressed. Evidence of inflammatory dysregulation (i.e., 
an imbalance between pro-and anti-inflammatory media-
tors) can be observed as early as the first trimester among 
pregnant women who later develop GDM [2, 3]. Sub-
clinical inflammation is also a major risk factor for future 
cardiovascular disease (CVD) in the general population, 
and women with a history of GDM are at increased risk 
of CVD later in life, potentially at least partly involving 
inflammatory mechanisms [4]. Although several studies 
have demonstrated increased levels of markers reflecting 
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vascular inflammation, such as sICAM-1 and sE-selec-
tion in women with a history of GDM [4, 5], the precise 
mechanism of vascular injury and CVD risk are not well 
understood.
Pentraxin 3 (PTX3) is an essential component of innate 
immunity and a member of the long pentraxin superfam-
ily, which are soluble, multifunctional pattern recognition 
proteins induced by various inflammatory stimuli [6]. In 
contrast to the short pentraxin C-reactive protein (CRP) 
which is primarily produced in the liver, PTX3 is pro-
duced locally in relevant cells such as endothelial cells, 
macrophages and granulocytes, at the site of inflamma-
tion. Although known to be a marker of inflammation, 
PTX3 has also been shown to possess anti-microbial 
and anti-inflammatory properties, and to be cardiopro-
tective [7, 8]. A number of anti-inflammatory molecules 
have been shown to modulate PTX3 expression, includ-
ing high density lipoprotein cholesterol (HDL-C) in 
endothelial cells [6]. Knockdown of PTX3 in apolipopro-
tein E-knockout mice is associated with cardiac damage, 
inflammation and atherosclerosis pointing to a protective 
effect of PTX3 [9]. Thus, the enhanced levels in patients 
with established CVD may reflect a beneficial response, 
correlating with the severity of the disease, to limit the 
extent of immune activation [6, 10], PTX3 serum levels 
are inversely correlated with several features of the meta-
bolic syndrome and obesity [11, 12].
Based on its relation to vascular inflammation, PTX3 
has been suggested to be involved in vascular complica-
tion during pregnancy. Indeed, PTX3 levels are mark-
edly elevated in women with preeclampsia [13] and type 
1 diabetes during pregnancy [14], and have been shown 
to correlate with the degree of glucose intolerance in 
women with GDM [15, 16]. However, PTX3 levels have 
not been prospectively evaluated during pregnancy and 
related to future CVD risk. As GDM women are more 
prone to develop CVD later in life and our overarching 
hypothesis is that this enhanced risk may start to develop 
or accelerate during pregnancy. We therefore measured 
circulating PTX3 in 300 women from a prospective 
cohort study at multiple times during pregnancy and at 
5-year follow-up. We hypothesized that GDM women 
would be present with regulated PTX3 levels and would 
be associated with CVD risk as reflected by lipid ratios at 
5 years follow-up.
Methods
Study population
The STORK study was a prospective cohort study with 
a longitudinal design in which 1031 low-risk women of 
Scandinavian heritage who gave birth at Oslo University 
Hospital Rikshospitalet between 2002 and 2008 were fol-
lowed throughout their pregnancy. Exclusion criteria 
included multiple pregnancy, known pre-gestational dia-
betes, severe chronic medical conditions (such as lung, 
cardiac, gastrointestinal or renal diseases), and pregnan-
cies complicated by major fetal malformations. Details 
about the study have been previously published [17]. 
Briefly, each pregnant woman had four antenatal visits 
at gestational age (GA) weeks 14–16, 22–24, 30–32, and 
36–38. Clinical data and blood samples were collected 
at each visit, processed, and stored at −80  °C until fur-
ther analysis. A 75 g oral glucose tolerance test (OGTT) 
was performed on all women at antenatal GA visit 
30–32 weeks.
The current study is a 5-year follow-up after the index 
pregnancy [18]. A total of 1031 participants from the 
original STORK cohort were invited to participate; the 
10 women who developed preeclampsia in the index 
pregnancy (including two who developed both GDM 
and preeclampsia) were not included in this analysis to 
avoid the obvious confounder of preeclampsia. Exclu-
sion criteria included pregnancy at the time of invita-
tion and/or delivery within the past year. Three hundred 
women agreed to participate. Written informed consent 
was obtained from all participants. All clinical investi-
gations were conducted according to the principles in 
the Declaration of Helsinki. The study was approved by 
the Regional Committee for Medical Research Ethics of 
Southern Norway in Oslo, Norway.
At the time of the 5-year follow-up visit, a fasting blood 
draw was performed to measure lipid profiles and a 75 g 
OGTT was conducted. For the purposes of this analysis, 
the term primiparous is used to identify women deliver-
ing their first child in the index pregnancy (nulliparous) 
or with only one prior delivery at 5-year follow-up.
Measurements of glycemic and lipid parameters
All 75  g OGTTs were performed in the morning after 
an overnight fast. Venous EDTA blood was analyzed 
at point of care using an Accu-Check Sensor glucom-
eter (Roche Diagnostics GmbH, Mannheim, Germany). 
Additional venous blood samples were allowed to clot 
for 30  min and the serum separated by centrifugation 
for 10  min at 3000g and stored at −80  °C. Glucose lev-
els were also measured from frozen serum samples col-
lected at 30–32  weeks using the hexokinase method 
(Hitachi Modular P800, Roche Diagnostics, Mannheim, 
Germany) at an accredited clinical chemistry laboratory 
at Oslo University Hospital Rikshospitalet, as previously 
reported [18]. For the 5-year follow-up study, we used 
the glucose data from the Accu-check Sensor glucom-
eter (Roche Diagnostics, Mannheim, Germany). Insulin 
levels in the stored samples were assayed in duplicate 
by RIA (Diagnostic Products Corporation, Los Ange-
les, CA, USA), as previously reported [18]. Levels of 
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apolipoprotein A (apoA), apoB, HDL-C, low density lipo-
protein cholesterol (LDL-C) (directly measurements), 
and triglycerides (TG) were measured from frozen serum 
samples at follow-up at an accredited clinical chemis-
try laboratory at Oslo University Hospital Rikshospita-
let. The ratios of TG/HDL-C and apoB/apoA are known 
risk factors for CVD [19, 20], and were calculated based 
on the above measurement. For PTX3 and CRP analy-
sis, we used fasting plasma from venous EDTA blood 
sampled on ice, centrifuged for 25 min at 3000g at 4 °C, 
separated, and stored at −80  °C until analyzed. PTX3 
and CRP levels were measured in duplicate using a com-
mercially available enzyme-linked immunosorbent assay 
(ELISA; R and D Systems, Minneapolis, MN, USA) in 
a 384 format using the combination of a SELMA (Jena, 
Germany) pipetting robot and a BioTek (Winooski, VT, 
USA) dispenser/washer. Absorption was read at 450 nm 
with wavelength correction set to 540 nm using an ELISA 
plate reader (Bio-Rad, Hercules, CA, USA).
Diagnosis of GDM
GDM was diagnosed on a 75 g OGTT using both the new 
IADPSG criteria and the old WHO criteria as follows: (1) 
IADPSG criteria: fasting plasma glucose (FPG) of 5.1–
6.9 mmol/L and 1 h plasma glucose ≥10.0 mmol/L or 2 h 
plasma glucose 8.5–11.0 mmol/L; and (2) WHO criteria: 
2  h plasma glucose  ≥7.8  mmol/L [21]. Insulin sensitiv-
ity was measured on the same samples collected at the 
time of OGTT using the Matsuda index (i.e., 10,000/
square root of [fasting glucose (mmol/L) × fasting insu-
lin (mU/L)] ×  [mean glucose (mmol/L) × mean insulin 
(mU/L)]) during OGTT. This index is a measure of whole 
body insulin sensitivity that has been validated against 
the euglycemic-hyperinsulinemic clamp [22]. β-cell func-
tion was assessed with the insulin secretion-sensitiv-
ity index (ISSI-2) [area under the curve (AUC) insulin 
(mU/L)0-120/glucose (mmol/L)0-120  ×  Matsuda], which 
has been validated against the disposition index from the 
intravenous GTT [23]. Homeostasis model assessment: 
insulin resistance(HOMA–IR) was calculated as fast-
ing insulin (mU/L) ×  fasting glucose (mmol/L)/22.5, as 
previously described by Matthews et al. [24]. The women 
diagnosed with GDM were not using any anti-diabetic 
medicine.
Measurements of arterial stiffness
All participants were examined at the 5-year follow-
up visit on the morning after fasting overnight. Aortic 
stiffness was assessed by means of PWV measurements 
using SphygmoCor (Atcor Medical, Sydney, Australia), 
a non-invasive technique with direct-contact pulse 
sensors. Aortic PWV was measured by sequential 
recordings of the arterial pressure waveform at the 
carotid and femoral arteries. The PWV was calculated as 
the distance between recording sites measured over the 
surface of the body (L), divided by the time interval (t) 
between the feet of the flow waves (PWV  =   L/t). The 
value was averaged over 10 cardiac cycles [25]. Only 
measurements that met the automatic quality control 
cutoff were used in the final analysis. Average SD of all 
measurements (mean time difference between carotid 
and femoral) was below 5  %. All measurements were 
performed by the author (TL), and we have no interob-
server variability.
Measurements of body fat composition
Total body composition was determined by dual-energy 
x-ray absorptiometry (DXA; GE Lunar Prodigy Densi-
tometer (software version 12.10), GE Medical Systems, 
Lunar Corp., Madison, WI, USA) and analyzed using 
enCORE software (version 14.10; GE Medical Systems), 
as previously described [18]. All DXA scans were per-
formed by the author (TL). CoreScan has been previ-
ously validated against volumetric computed tomography 
[26, 27]. For measuring android fat, a region of interest 
(ROI) was defined with the caudal limit at the top of the 
iliac crest and the cephalic limit at the base of the skull. 
Android ROI contains both visceral (VAT) and subcuta-
neous adipose tissue (SAT). The software estimates the 
quantity of SAT in the android ROI. VAT was computed 
by subtracting SAT from the total android fat. The fat 
mass data from DXA was transformed to volume using 
a constant correction factor (0.94 g/cm3) consistent with 
the density of adipose tissue [26]. All VAT under 50 g was 
set to 50 g since the DXA measurement is unreliable in 
the low range visceral fat content [28].
Statistical analysis
Statistical analyses were conducted using SPSS for Win-
dows, version 21.0 (Chicago, IL, USA). Data are expressed 
as mean  ±  SD when normally distributed and median 
(25th, 75th percentile) when skewed. Comparison 
between women with and without a history of GDM was 
performed using t test or Mann–Whitney U depending 
on distribution, and Chi square test for categorical vari-
ables. Univariate and stepwise (probability of F to-enter 
0.1 -remove 0.15) linear regression analyses were carried 
out on log transformed variables (if skewed) and results 
given as standardized regression coefficients. Only vari-
ables below p < 0.2 were included in the stepwise multi-
variable models. Logistic regression was used to calculate 
odds ratios for risk factors according to established cut-
offs for the apoB/apoA and TG/HDL-C ratio. Two-tailed 
p values <0.05 were considered significant.
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Results
Table  1 shows the characteristics of the study popula-
tion during the index pregnancy and at the time of the 
5-year follow-up visit stratified into those women who 
did and did not have GDM in the index pregnancy using 
both the IADPSG (50 with and 234 without GDM) and 
WHO criteria (31 with and 253 without GDM), based on 
the OGTTs. As evident from Table 1, women with GDM 
based on the IADPSG criteria were on average older and 
had a higher body mass index (BMI) both in the index 
pregnancy and at follow-up, while women with GDM 
based on the WHO criteria had a higher BMI at follow-
up compared to their non-GDM counterparts. Women 
belonging to both criteria were more frequently smokers 
at follow-up.
Women with GDM have lower plasma PTX3 in early 
pregnancy and at follow‑up compared to non‑GDM 
women
Plasma PTX3 levels increased during pregnancy in 
both GDM and non-GDM women from 14–16  weeks 
to 36–38 weeks (p < 0.001 for all time points), and was 
lower at 5 years follow-up compared to during pregnancy 
(Fig. 1A). While this pattern was seen in the study group 
as a whole, women with GDM had significantly lower 
PTX3 levels than those without GDM at 14–16  weeks 
and 22–24  weeks as well as at 5-year follow-up when 
using the WHO criteria, but only at 5-year follow-up 
when using the IADPSG criteria (Additional file 1: Table 
S1). For CRP, no differences between GDM and non-
GDM women using WHO criteria was observed during 
Table 1 Characteristics of the study population according to the new GDM IADPSG criteria and the old GDM WHO criteria
a Visit 1. Data given as mean ± SD when normal distributed and median (25th, 75th) when skewed distributed. Comparison between women with GDM and non-
GDM were performed using t test for normal distributed variables, Mann–Whitney U for non-distributed continuous variables, and Chi test for categorical variables
* p < 0.05
** p < 0.001
Variable Visit 3 (week 30–32) in the index pregnancy Follow‑up visit
GDM Non‑GDM GDM Non‑GDM
N= IADPSG 50 234 50 234
WHO 31 253 31 253
Follow-up time (years) IADPSG 5.1 (4.6, 5.3) 4.8 (4.4, 5.4)
WHO 5.0 (4.5, 5.4) 4.8 (4.4, 5.4)
Age (years)a IADPSG 33.6 ± 4.3 32.0 ± 3.7* 38.9 ± 4.4 37.4 ± 3.7*
WHO 33.1 ± 3.7 32.2 ± 3.8 38.6 ± 3.8 37.5 ± 3.8
Height (cm)a IADPSG 169 ± 6 169 ± 6 168 ± 6 169 ± 6
WHO 168 ± 5 169 ± 6 168 ± 5 169 ± 6
BMI (kg/m2) IADPSG 28.2 (26.8, 30.8) 26.2 (23.7, 28.4)** 24.7 (22.5, 28.0) 22.6 (20.8, 24.6)**
WHO 27.8 (25.7, 31.2) 26.4 (23.9, 28.6) 24.1 (21.7, 28.1) 22.8 (20.9, 25.1)*
Primipara n (%) IADPSG 22 (44.0) 118 (51.1) 6 (12.0) 26 (11.1)
WHO 18 (60.0) 122 (48.6) 6 (19.3) 26 (10.3)
Family history heart disease n (%) IADPSG 31 (64.5) 134 (57.7)
WHO 22 (75.9) 143 (57.0)
Family history diabetes n (%) IADPSG 17 (34.0) 71 (30.3)
WHO 13 (41.9) 75 (29.6)
Currently smoking n (%) IADPSG 1 (2.0) 7 (3.0) 13 (26.0) 35 (15.0)*
WHO 1 (3.2) 7 (2.8) 9 (29.0) 39 (15.4)*
Previous smoker n (%) IADPSG 14 (28.0) 39 (16.7) 15 (30.0) 50 (21.3)
WHO 8 (25.8) 45 (17.8) 8 (25.8) 57 (22.5)
Systolic blood pressure (mmHg) IADPSG 115 (105, 120) 110 (105, 120) 110 (100, 130) 110 (100, 120)
WHO 110 (100, 120) 110 (105, 120) 110 (100, 130) 110 (100, 120)
Diastolic blood pressure (mmHg) IADPSG 70 (60,73) 70 (60, 70) 70 (65, 75) 70 (60, 75)
WHO 70 (60, 70) 70 (60, 70) 70 (65, 80) 70 (60, 75)
Mean arterial pressure (mmHg) IADPSG 83.3 (78.3, 88.3) 81.7 (76.7, 86.7) 83.3 (76.7, 92.1) 83.3 (76.7,88,3)
WHO 82.5 (77.5, 86.7) 83.3 (76.7, 86.7) 83.3 (78.7, 95.0) 83.3 (76.7, 88.3)
Pulse pressure (mmHg) IADPSG 45 (40,50) 43 (40,50) 40 (40,50) 40 (40,50)
WHO 40 (40,50) 45 (40,50) 40 (35,50) 40 (40,50)
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pregnancy, but GDM women had higher CRP at 5 years 
follow-up (Fig.  1B). However, using the IADPSG crite-
ria, GDM women had higher CRP levels at 14–16, 22–24 
and 30–32  weeks (Additional file  1: Table S1). We have 
previously demonstrated enhanced CVD risk in GDM 
women based on the WHO criteria compared to the 
IADPSG criteria [29]. Subsequent analysis was therefore 
restricted to women diagnosed with GDM based on the 
WHO criteria. Consistent with prior reports [13], we also 
found that women with preeclampsia in the index preg-
nancy (n  =  10) had markedly higher circulating PTX3 
levels, but not CRP levels at all time points in pregnancy; 
PTX3 (median 25th, 75th); 3.85 (3.49, 6.42) ng/mL at 
14–16  weeks, 5.03 (3.71, 6.19) ng/mL at 22–24  weeks, 
7.33 (5.45, 10.40) ng/mL at 30–32 weeks, and 11.49 (6.73, 
17.71) ng/mL at 36–38 weeks (p < 0.05 compared to non 
GDM), but not at 5-year follow up [3.53 (2.28, 4.82) ng/
mL; p = 0.16]. Women with preeclampsia were excluded 
from further analysis.
Associations between PTX3 and clinical characteristics 
in pregnancy
We next evaluated the association between PTX3 levels 
and clinical variables at each of the four antenatal visits 
in pregnancy (Table 2), and found that BMI was consist-
ently negatively associated with PTX3 levels at each visit. 
Systolic blood pressure (BP) was inversely associated 
with PTX3 levels at 30–32 weeks. No associations were 
found between PTX3 levels and CRP, parity or smoking 
status prior to pregnancy. Indices of glucose metabolism 
calculated from the OGTT at 30–32 weeks revealed that 
PTX3 levels was positively associated with insulin sensi-
tivity (r = 0.23, p < 0.001) and β-cell function (r = 0.18, 
p  =  0.003), and negatively with insulin resistance 
(r = −0.23, p < 0.001). Conversely, CRP was consistently 
positively associated with BMI at all time-points during 
pregnancy (r = 0.25–0.27, p < 0.001) and insulin resist-
ance at 30–32 weeks (r = 0.25, p < 0.001) and negatively 
associated with insulin sensitivity (r = −0.28, p < 0.001) 
and β-cell function (r = −0.14, p = 0.021).
Associations between PTX3 levels and cardio‑metabolic 
risk markers at 5‑year follow‑up
As shown in Table  3, and observed during pregnancy 
PTX3 levels were negatively correlated with BMI and 
showed a similar association with VAT. Further, PTX3 
was positively correlated with insulin sensitivity and neg-
atively correlated with insulin resistance, although these 
associations were modest. We recently demonstrated 
that these GDM women are characterized by dyslipi-
demia and increased arterial stiffness [29]. PTX3 levels 
were negatively correlated with arterial stiffness, apoB 
and LDL-C, and positively correlated with the athero-
protective lipids apoA and HDL-C. No association was 
found between PTX3 and CRP. Thus, circulating PTX-3 
may reflect a composite of different factors associated 
with metabolic and in particular cardiovascular risk.
Predictors of CVD risk as reflected by lipid 
and apolipoprotein ratios
As shown above, apoA and apoB were asssociated with 
PTX3 at 5-year follow-up (Table 3). The apoB/apoA ratio 
is a well-established biomarker for the development of 
atherosclerotic disorders as well as adverse CVD outcome 
[19]. In addition, we have recently demonstrated that 
GDM women have significantly higher TG/HDL-C ratios, 
a biomarker that may reflect enhanced risk of metabolic 
complications and risk of CVD [29]. The LDL/HDL ratio 
is also a CVD risk indicator, with a better predictive value 
than isolated parameters used independently, particu-
larly LDL [30]. We therefore next investigated if PTX3 
was associated with these ratios using an apoB/apoA 
ratio of >0.59 to define moderate-risk and >0.79 to define 
high-risk [19], a cut-off of >3.0 for LDL/HDL [30] and a 
cut-off of >1.09 for the TG/HDL ratio [20]. As shown in 
Fig. 2a, a stepwise risk increase using the apoB/apoA ratio 
as a proxy for CVD was observed with decreasing PTX3 
levels at 5-year follow-up. Similar but more modest dif-
ference was observed for the LDL/HDL and TG/HDL-C 
ratios (Fig.  2a). Additional file  1: Table S2 shows the 
Fig. 1 Circulating A PTX3 and B CRP levels in pregnancy and at 
5-year follow-up between GDM (WHO) and non-GDM. FU, follow-
up. Date is given as median and 25th/75th percentile. *p < 0.05, 
**p < 0.01 compared with non-GDM group. ap < 0.05, bp < 0.01, 
cp < 0.001 vs. week 14–16 within group
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univariate odds ratios (ORs) for PTX3, CRP and other CV 
risk factors at 5 years follow-up in relation to these ratios. 
In addition to PTX3, the strongest predictors for CVD 
risk were BMI and systolic BP, with some associations 
for parity and smoking on some ratios. Figure 2b shows 
multivariable models and demonstrates that, at 5-year fol-
low-up, PTX3 remains significantly associated with CVD 
risk even after accounting for BMI and systolic BP. No 
association between CRP and these ratios was observed.
Prediction of CVD risk at 5‑year follow‑up by PTX3 levels 
during the index pregnancy
We finally assessed if circulating PTX3 at different time-
points during pregnancy could predict moderate or high 
CVD risk, based on apoB/apoA ratio, in univariate and 
multivariable analysis, adjusting for BMI and systolic BP, 
acquired at the time of PTX3 measurement. As shown in 
Fig. 2c, low PTX3 levels were associated with moderate-
risk and especially high-risk for CVD from 14–16 weeks 
until 30–32  weeks, with only a minor effect of adjust-
ment. A similar patterns was observed for the LDL/HDL 
ratio (Fig. 2d). When evaluating CVD risk as reflected by 
the TG/HDL ratio no association with PTX3 levels dur-
ing pregnancy was found (Fig.  2e). The ORs for these 
associations are given in Additional file 1: Table S3. ROC 
curves with AUC data for PTX3 and prediction of apoB/
apoA and the LDL/HDL ratio at 5  years follow-up are 
given in Additional file 1: Figure S1. For the early time-
points, PTX3 gives good discrimination (AUC 0.77–0.81) 
of high CV risk according to the apoB/apoA  ≥0.79, 
which supports the conclusion from the univariate and 
multivariable analysis. The discrimination for the LDL/
HDL ratio ≥3.0 gave a more modest discrimination.
Discussion
Our study demonstrates that circulating PTX3 levels 
are lower early in pregnancy and at 5-year follow-up in 
women who have GMD as compared with those who do 
not. PTX3 was consistently negatively correlated with 
BMI during pregnancy, and was associated with multiple 
metabolic risk factors for CVD at 5-year follow-up. Low 
PTX3 levels in pregnancy were correlated with enhanced 
future CVD risk as estimated by the apoB/apoA and 
LDL/HDL ratio at 5-year follow-up, and this association 
Table 2 Association between PTX3 levels in pregnancy and clinical characteristics throughout pregnancy
a  Primipara/multipara
b  Previous and current
Variables 14–16 weeks 22–24 weeks 30–32 weeks 36–38 weeks
r p r p r p r p
Age −0.01 0.851 −0.01 0.982 0.05 0.422 0.03 0.625
BMI −0.21 <0.001 −0.23 <0.001 −0.18 0.002 −0.23 <0.001
CRP 0.07 0.261 0.05 0.402 −0.03 0.664 0.00 0.968
Paritya −0.03 0.581 −0.03 0.636 0.01 0.911 −0.03 0.587
Smokingb −0.08 0.206 −0.02 0.743 −0.03 0.651 −0.03 0.606
Systolic BP −0.06 0.289 −0.06 0.328 −0.16 0.006 −0.03 0.595
Diastolic BP −0.02 0.689 −0.06 0.261 −0.05 0.418 0.05 0.428
Table 3 Associations between  PTX3 and  cardio-metabolic 
risk factors 5-year follow-up
a Primipara/multipara
b Previous and current
Variables Univariate
r p
Follow-up 0.04 0.516
Age 0.01 0.997
Diabetes in family 0.06 0.601
Heart disease in family −0.07 0.507
BMI −0.29 <0.001
Paritya 0.05 0.437
Smokingb 0.10 0.105
GDM (WHO criteria) −0.16 0.006
Systolic BP (mmHg) −0.12 0.055
Diastolic BP (mmHg) −0.05 0.447
Insulin sensitivity 0.13 0.033
Insulin resistance −0.12 0.046
β-cell function 0.11 0.063
PWV −0.18 0.002
apoA 0.22 <0.001
apoB −0.25 <0.001
LDL −0.23 <0.001
TG −0.10 0.082
HDL 0.22 <0.001
CRP 0.05 0.405
Visceral fat −0.29 <0.001
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was independent of BMI and CRP. Our findings suggest 
that low PTX3 levels early in pregnancy, and in particular 
in GDM could confer enhanced long-term CVD risk.
Comparison with previous studies
A major finding in our study was that PTX3 levels were 
decreased in women with GDM compared to non-GDM 
women, in particular at 5-year follow-up. This is in 
contrast to two recent studies showing no difference or 
increased PTX3 levels in GDM and compared with non-
GDM women. The reason for this discrepancy is unclear, 
but could involve a lower number of patients with GDM 
and in particular of controls in the two other studies, and 
notably in one of the studies there was no differences 
in lipid values, BMI or measures of glucose metabolism 
between GDM and non-GDM women suggesting that 
Fig. 2 Low circulating PTX3 during pregnancy and at 5-year follow-up is associated with increased cardiovascular disease (CVD) risk. a PTX3 and 
CRP levels at follow-up according the TG/HDL-C ratio representing increased CVD risk (>1.09), LDL/HDL-C ratio >3.0 and apoB/apoA ratio represent-
ing low (<0.60), moderate (≥ 0.60–0.79) and high risk (≥0.80) for coronary artery disease (CAD). *p < 0.05, **p < 0. 01, ***p < 0.001 vs. reference 
group (green); ††p < 0.01 vs. intermediate risk (≥0.59 <0.79). b Adjusted risk models for PTX3, BMI, systolic BP and CRP at follow-up for moderate and 
high risk as reflected by apoB/apoA ratio, LDL/HDL-C ratio and the TG/HDL-C ratio according to cut-offs in A. c Univariate (red circles) and adjusted 
(blue circles) models for moderate and increased CVD risk as reflected by apoB/apoA ratios by PTX3 during pregnancy. d Univariate (red circles) 
and adjusted (blue circles) models for increased CVD risk as reflected by LDL/HDL-C ratio by PTX3 during pregnancy. e Univariate (red circles) and 
adjusted (blue circles) models for increased CVD risk as reflected by the TG/HDL-C ratio by PTX3 during pregnancy. The adjusted analysis included 
BMI and systolic BP acquired at the same time as the PTX3 measurement. PTX3, BMI, systolic BP and CRP are expressed as log change per SD. For 
PTX3 the inverse function is given to reflect increasing risk with lower levels. *p < 0.05, **p < 0. 01, ***p < 0.001 vs. reference group
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they are studying a milder GDM phenotype, which is also 
supported by the GDM diagnostic criteria used (ADA 
and NDDG) [15, 16]. Furthermore, while Yilidrim et  al. 
[16] observed a positive correlation between PTX3 lev-
els and response to the glucose challenge test, we found 
positive correlations with β cell function and insulin sen-
sitivity and a negative correlation with insulin resistance, 
suggesting a potential beneficial effect of PTX3. A protec-
tive role for PTX3 in normal pregnancy, with increased 
levels closer to gestation, as observed in our study, has 
been reported in several other publications [31, 32].
Although not the focus of our study, we also observed 
markedly enhanced PTX3 levels in preeclamptic women 
at all time points, supporting a number of publications 
showing that PTX3 is closely correlated with the severity 
and progression of preeclampsia [13]. This may reflect a 
feedback mechanism aimed at counterbalancing overac-
tive pro-inflammatory signals [6, 8], and some studies have 
suggested that the increased levels of PTX3 observed in 
preeclampsia may have a placental origin coming from the 
increased number of macrophages in the placental bed [13].
PTX3 and metabolic profile
Obesity and GDM are both chronic low-grade inflam-
matory states [33] and elevated circulating markers of 
endothelial dysfunction are present in young females with 
a history of GDM [34]. This chronic inflammatory state 
appears to trigger insulin resistance in the skeletal muscles 
of obese individuals. We have previously shown that the 
GDM women have higher BMI and visceral fat content at 
5-year follow-up [18]. The negative correlation between 
BMI and PTX3 levels during pregnancy and at 5-year fol-
low-up supports recent studies demonstrating low PTX3 
levels in patients with the metabolic syndrome and obesity 
[11, 35]. Furthermore, recent studies investigating the asso-
ciation between plasma PTX3 levels and insulin resistance 
in lean, overweight, and obese individuals [35, 36] supports 
our data of a negative correlation with glucose intolerance. 
Miyaki et al. [37] showed that PTX3 production in adipose 
tissue and skeletal muscles of diabetic obese mice was sig-
nificantly lower than in control mice suggesting that PTX3 
may play a role in promoting insulin sensitivity by regulat-
ing glucose transport proteins. It is tempting to hypothesize 
that similar mechanisms could be operating in women with 
GDM. The observation that women diagnosed with GDM 
based on WHO criteria are the subjects with the lowest 
PTX3 levels during pregnancy and follow-up, may thus 
indicate that low PTX3 might be a marker of more severe 
metabolic impairment and cardiovascular risk.
Cardioprotective effects of PTX3
We have recently demonstrated that women with GDM 
have a moderately increased arterial stiffness, an early 
indicator of CVD risk, at 5-year follow-up [29]. Circu-
lating PTX3 is now accepted as a major CVD risk factor, 
providing independent prognostic information in popula-
tions with established CVD. However, the precise role of 
PTX3 in vascular diseases is unknown and its relevance in 
patients without manifest CVD is less well established. Fur-
thermore, several experimental models and in  vitro stud-
ies support a cardioprotective function of PTX3 [7]. Thus, 
PTX3 deficiency is associated with increased inflammation, 
cardiac damage, and atherosclerosis. PTX3 deficient mice 
develop larger atherosclerotic lesions compared to con-
trols [6]. In addition, PTX3 may inhibit complement acti-
vation and increase the progression of atherosclerosis [38]. 
Our finding of a negative correlation between PTX3 levels 
and arterial stiffness as estimated by PWV, and as previ-
ously shown in overweight subjects [11], may lend clinical 
support to a cardioprotective effect of PTX3 and further 
suggests an adverse effect of low PTX3 levels in GDM on 
early atherosclerotic progression. Tombetti et al. [39] found 
increased PTX3 in patients with Takayasuartiritis and 
increased vascular inflammation. Recently, Camozzi et  al. 
[40], demonstrated a protective role of PTX3 after ves-
sel injury, limiting intimal thickening. Taken together, this 
suggests that there is a contradiction between a condition 
involving vascular inflammation (e.g. overt atherosclerosis, 
large-vessel vasculitis, and pre-eclampsia) and its associa-
tion with metabolic variables (lipid profiles, insulin resist-
ance and β-cell function, BMI) and, as mentioned above, in 
a vascular inflammatory condition PTX3 might be enhance 
a protective feedback mechanism activated by inflamma-
tion and vascular injuries. While some anti-diabetic drugs 
has been shown to have beneficial effects on markers of 
vascular inflammation [41] and PTX3 decreased after 
24  weeks of administration of sitagliptin [42], the effects 
of anti-diabetic treatment on PTX3 in GDM would be of 
interest. It is clear that the regulation of PTX3 in pregnancy 
is complex, and the different profiles observed in GDM 
and preeclampsia patients may reflect contributions from 
different sources depending on the presence and extent of 
acute or chronic inflammatory conditions.
PTX3 in early pregnancy as a predictor of future CV risk
At 5-year follow-up, women with GDM showed an unfa-
vorable lipid profile, with low levels of HDL-C and apoA 
and high levels of TG, as also demonstrated by others 
[43]. We have previously reported enhanced TG/HDL-C 
ratio as a marker of cardiometabolic risk in women with 
a history of GDM [29]. In the present study we showed 
that at 5-year follow-up, PTX3 levels correlated well with 
apolipoprotein levels. Low serum PTX3 levels were par-
ticularly prevalent in patients with an enhanced apoB/
apoA ratio, representing a pro-atherogenic lipid profile. 
Importantly, when investigating PTX3 in pregnancy as a 
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predictor of the apoB/apoA ratio at 5-year follow-up, we 
found that PTX3 was associated with an increase in this 
ratio as early as 14–16 weeks of gestation, and this asso-
ciation remained after adjusting for BMI and systolic BP. 
This suggests that the effects of low PTX3 on CVD risk do 
not merely reflect a different body composition. One limi-
tation of our study is that we did not have standard lipid 
profiles at the different timepoints in pregnancy. Also, as 
the women in our study were young with no CVD events, 
a longer follow-up time would reveal if low PTX3 in preg-
nancy was associated with actual CV events.
Potential mechanisms
Although the precise determinants of PTX3 levels 
in pregnancy remain unknown, a range of metabolic 
risk factors were shown to be independent predictors 
of PTX3 at 5-year follow-up. As such, the low levels 
of PTX3 early in pregnancy in women with GDM are 
likely the result of a composite of metabolic derange-
ments. HDL-C induces PTX3 expression in endothe-
lial cells in  vitro [44], and HDL-C levels reportedly 
decrease in GDM as early as the second trimester [45]. 
The lack of association with CRP supports that a poten-
tial beneficial effects of PTX3 may be independent of its 
anti-inflammatory effects. It is possible that low HDL-C 
levels could contribute to low PTX3 levels which again 
may contribute to an unfavorable lipid profile. Amongst 
several functions, HDL-C may promote cholesterol efflux 
from peripheral tissues and transport it to the liver for 
excretion, thus protecting against CVD. Although our 
clinical data do not permit any mechanistic insight into 
the role of PTX3 in pregnancy and GDM, we nonetheless 
speculate on its potential role by integrating the cardio-
metabolic effects derived from experimental studies and 
clinical observations as described above in Fig. 3.
In conclusion, our results show that plasma PTX3 con-
centrations in women with GDM are significantly lower 
than those in non-GDM women, both in early pregnancy 
and at 5-year follow-up. Further, circulating PTX3 levels 
in early pregnancy can predict CVD risk using the apoB/
apoA ratio as a proxy at 5 years postpartum. Larger pro-
spective studies are needed to investigate the mechanism 
by which PTX3 levels are altered in women with GDM and 
to evaluate its prognostic potential for future CVD risk.
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